![Zi Qiang Cheng](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Zi Qiang Cheng
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Zion Pharma Ltd.
![]() Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Vorstandsvorsitzender | 01.01.2018 | - |
Vorsitzender | 01.01.2018 | - | |
Gründer | 01.01.2018 | - |
Karriereverlauf von Zi Qiang Cheng
Statistik
International
China | 2 |
Operativ
Chief Executive Officer | 1 |
Chairman | 1 |
Founder | 1 |
Sektoral
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Zion Pharma Ltd.
![]() Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Commercial Services |
- Börse
- Insiders
- Zi Qiang Cheng
- Erfahrung